Pancreatic Cancer Research

ResearcherUniversity of MichiganActive in the last 2 years

Marina Pasca di Magliano

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0001-9632-9035; OpenAlex author ID A5070137893; NIH RePORTER profile ID 9699074. Sources: funder_awards.

Their work

Papers
79 (first author 11, last author 23)
Trials
0
Grants
13
Labs led
3
Collaborators
220
Papers, trials and grants by year

2009: 1 grant · 2010: none · 2011: 1 paper · 2012: 2 papers · 2013: 3 papers, 1 grant · 2014: 3 papers · 2015: 2 papers · 2016: 1 paper · 2017: 2 papers · 2018: 4 papers · 2019: 3 papers, 1 grant · 2020: 8 papers, 1 grant · 2021: 12 papers, 1 grant · 2022: 8 papers, 2 grants · 2023: 7 papers · 2024: 5 papers · 2025: 7 papers, 1 grant · 2026: 11 papers, 5 grants

Papers 50 of 79

  1. Pancreatic ductal adenocarcinoma: The Vision of Heracles. Co-author DOI 10.1016/j.ccell.2026.07.014↗
  2. A stromal PAI1-tPA axis orchestrates immunosuppression in pancreatic cancer. Co-author DOI 10.1126/sciadv.aea6734↗
  3. Wilms Tumor 1-Expressing Stromal Cells Promote Pancreatic Cancer Progression. Last author DOI 10.1158/0008-5472.can-25-1014↗
  4. Longitudinal Analysis of Matched Patient Biospecimens Reveals Neural Reprogramming of Cancer-Associated Fibroblasts Following Chemotherapy in Pancreatic Cancer. Co-author DOI 10.1158/0008-5472.can-26-0823↗
  5. Aryl Hydrocarbon Receptor Ligands Drive Pancreatic Cancer Initiation and Progression through Protumorigenic T-cell Polarization. Co-author DOI 10.1158/2159-8290.cd-25-0377↗
  6. Asynchronous Evolution of Epithelium and Stroma Differentiates Precursor Lesions from Pancreatic Cancer. Last author DOI 10.1158/2159-8290.cd-25-2001↗
  7. Targeting CCR1 Remodels the Tumor Microenvironment and Relieves Immunosuppression in Pancreatic Cancer. Last author DOI 10.1158/2326-6066.cir-25-1300↗
  8. Systemic immunosuppression limits NK cell therapy efficacy in pancreatic cancer. Co-author DOI 10.1186/s12943-025-02340-8↗
  9. Hypoxia Impairs CD8+ T Cell Fitness and Is Associated with a Dysfunctional CD8+ T Cell State in Pancreatic Cancer. First author DOI 10.3390/cancers18101508↗
  10. Hypoxia-Induced Fibroblast IL-6 Promotes Immunosuppressive Macrophage Phenotypes in Pancreatic Cancer. Co-author DOI 10.3390/cells15080683↗
  11. Oncogenic KRAS-MAPK signaling sustains a CD73 dependent therapeutic vulnerability in pancreatic cancer Co-author DOI 10.64898/2026.10.20.760559↗
  12. Co-treatment of ticagrelor and anti-PD-1 immunotherapy in tumor-associated macrophages reduces pancreatic cancer cell growth and migration through the TGF-β1/S… Co-author DOI 10.1016/j.biopha.2025.118695↗
  13. Primary and metastatic cellular landscapes in human pancreatic cancer. Last author DOI 10.1016/j.isci.2025.113012↗
  14. Targeting PIKfyve-driven lipid metabolism in pancreatic cancer. Co-author DOI 10.1038/s41586-025-08917-z↗
  15. DUSP6 is upregulated in metastasis and influences migration and metabolism in pancreatic cancer cells. Co-author DOI 10.1038/s41598-025-12967-8↗
  16. Two Shots on Goal: Combination of RAS Inhibition and Immunotherapy Drives Long-term Remission in Pancreatic Cancer. First author DOI 10.1158/2159-8290.cd-25-0878↗
  17. Multidimensional analyses identify genes of high priority for pancreatic cancer research. Co-author DOI 10.1172/jci.insight.174264↗
  18. Aspartate Transaminases Are Dispensable for Pancreatic Development and Pancreatic Cancer Progression Co-author DOI 10.64898/2025.12.17.694916↗
  19. KRAS-mediated upregulation of CIP2A promotes suppression of PP2A-B56α to initiate pancreatic cancer development. Co-author DOI 10.1038/s41388-024-03196-w↗
  20. From Inception to Malignancy: the Co-evolution of Pancreatic Cancer and Its Immunosuppressive Microenvironment. Last author DOI 10.1158/0008-5472.can-24-2732↗
  21. Pancreatic Cancer-Associated Fibroblasts: Where Do We Go from Here? Co-author DOI 10.1158/0008-5472.can-24-2860↗
  22. KRT17high/CXCL8+ Tumor Cells Display Both Classical and Basal Features and Regulate Myeloid Infiltration in the Pancreatic Cancer Microenvironment. Last author DOI 10.1158/1078-0432.ccr-23-1421↗
  23. Notch Signaling Regulates Immunosuppressive Tumor-Associated Macrophage Function in Pancreatic Cancer. Co-author DOI 10.1158/2326-6066.cir-23-0037↗
  24. KMT2D links TGF-β signaling to noncanonical activin pathway and regulates pancreatic cancer cell plasticity. Co-author DOI 10.1002/ijc.34528↗
  25. Pancreatic cancer: Advances and challenges. Co-author DOI 10.1016/j.cell.2023.02.014↗
  26. Tyrosine Sulfation: A New Player and Potential Target in Pancreatic Cancer. First author DOI 10.1016/j.jcmgh.2023.06.007↗
  27. Calligraphy tool offers clues to the origin of pancreatic cancer. First author DOI 10.1038/d41586-023-02518-4↗
  28. Uridine-derived ribose fuels glucose-restricted pancreatic cancer. Co-author DOI 10.1038/s41586-023-06073-w↗
  29. WNT signaling in the tumor microenvironment promotes immunosuppression in murine pancreatic cancer. Last author DOI 10.1084/jem.20220503↗
  30. Arginase 1 is a key driver of immune suppression in pancreatic cancer. Last author DOI 10.7554/elife.80721↗
  31. KDM6A Regulates Cell Plasticity and Pancreatic Cancer Progression by Noncanonical Activin Pathway. Co-author DOI 10.1016/j.jcmgh.2021.09.014↗
  32. Hypoxia promotes an inflammatory phenotype of fibroblasts in pancreatic cancer. Co-author DOI 10.1038/s41389-022-00434-2↗
  33. Differential integrated stress response and asparagine production drive symbiosis and therapy resistance of pancreatic adenocarcinoma cells. Co-author DOI 10.1038/s43018-022-00463-1↗
  34. KDM6A Loss Recruits Tumor-Associated Neutrophils and Promotes Neutrophil Extracellular Trap Formation in Pancreatic Cancer. Co-author DOI 10.1158/0008-5472.can-22-0968↗
  35. GOT2: An Unexpected Mediator of Immunosuppression in Pancreatic Cancer. First author DOI 10.1158/2159-8290.cd-22-0845↗
  36. Combinatorial Gli activity directs immune infiltration and tumor growth in pancreatic cancer. Co-author DOI 10.1371/journal.pgen.1010315↗
  37. Metabolic requirement for GOT2 in pancreatic cancer depends on environmental context. Co-author DOI 10.7554/elife.73245↗
  38. Multiomic characterization of pancreatic cancer-associated macrophage polarization reveals deregulated metabolic programs driven by the GM-CSF-PI3K pathway. Co-author DOI 10.7554/elife.73796↗
  39. Immunotherapy for pancreatic ductal adenocarcinoma. Co-author DOI 10.1002/jso.26312↗
  40. The Gustatory Sensory G-Protein GNAT3 Suppresses Pancreatic Cancer Progression in Mice. Co-author DOI 10.1016/j.jcmgh.2020.08.011↗
  41. Myeloid Cell Mediated Immune Suppression in Pancreatic Cancer. First author DOI 10.1016/j.jcmgh.2021.07.006↗
  42. Loss of activating transcription factor 3 prevents KRAS-mediated pancreatic cancer. Co-author DOI 10.1038/s41388-021-01771-z↗
  43. GOT1 inhibition promotes pancreatic cancer cell death by ferroptosis. Co-author DOI 10.1038/s41467-021-24859-2↗
  44. New Insights Into Pancreatic Cancer: Notes from a Virtual Meeting. Co-author DOI 10.1053/j.gastro.2021.04.082↗
  45. Nutrient profiling reveals extracellular uridine as a fuel for pancreatic cancer through uridine phosphorylase 1 Co-author DOI 10.1101/2021.06.07.447448↗
  46. ATDC binds to KEAP1 to drive NRF2-mediated tumorigenesis and chemoresistance in pancreatic cancer. Co-author DOI 10.1101/gad.344184.120↗
  47. Apolipoprotein E Promotes Immune Suppression in Pancreatic Cancer through NF-κB-Mediated Production of CXCL1. Co-author DOI 10.1158/0008-5472.can-20-3929↗
  48. Inhibition of Hedgehog Signaling Alters Fibroblast Composition in Pancreatic Cancer. Last author DOI 10.1158/1078-0432.ccr-20-3715↗
  49. Pancreatic cancer is marked by complement-high blood monocytes and tumor-associated macrophages. Last author DOI 10.26508/lsa.202000935↗
  50. Therapeutic Potential of Targeting Stromal Crosstalk-Mediated Immune Suppression in Pancreatic Cancer. First author DOI 10.3389/fonc.2021.682217↗

Grants 13

  1. Mechanisms of myeloid cell driven pancreatic plasticity and carcinogenesis R01CA268426↗
  2. Dissecting the role of Notch signaling in the pancreatic cancer microenvironment. R01CA271510↗
  3. Investigating GLI transcription factors as regulators of the pancreatic cancer microenvironment R01CA275182↗
  4. Fibroblast orchestration of the immune response in pancreatic cancer U01CA274154↗
  5. TBEL Project 3 U54CA274371↗
  6. Targeting the fibroblast-immune cell crosstalk to relieve immune suppression in the pancreatic cancer microenvironment R01CA260752↗
  7. Tumor Microenvironment Determinants of Resistance to KRAS/FAK Inhibition AWARD pancan:2022-marina-pasca-di-magliano-phd-tumor-microenvironment-determinants-of-r
  8. Establishment and regulation of the immune suppressive microenvironment in pancreatic cancer R01CA264843↗
  9. Interrupting Cellular Crosstalk in the Immunosuppressive Microenvironment of Pancreas Cancer U01CA224145↗
  10. Mechanisms of Pancreatic Inflammation, Tissue Repair and Carcinogenesis R01CA151588↗
  11. Dosage-Dependent Hedgehog Signaling in Pancreatic Cancer R01CA198074↗
  12. Novel Hedgehog Receptors As Therapeutic Targets In Pancreatic Cancer R21CA167122↗
  13. Notch Signaling in Pancreatic Cancer Initiation and Progression AWARD pancan:2009-marina-pasca-di-magliano-phd-notch-signaling-in-pancreatic-cancer-ini

Closest collaborators

The 25 strongest of 220 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Filip Bednar · 26 shared papers, 1 shared grant, 2012–2026 · strength 5.49
  2. Timothy L. Frankel · 15 shared papers, 2 shared grants, 2018–2026 · strength 4.34
  3. Howard C. Crawford · 23 shared papers, 2 shared grants, 2019–2026 · strength 4.31
  4. Costas Andreas Lyssiotis · 24 shared papers, 1 shared grant, 2018–2026 · strength 4.15
  5. Eileen S. Carpenter · 21 shared papers, 2020–2026 · strength 3.26
  6. Benjamin Allen · 6 shared papers, 3 shared grants, 2013–2026 · strength 2.44
  7. Jiaqi Shi · 14 shared papers, 2019–2026 · strength 2.28
  8. Yaqing Zhang · 21 shared papers, 2012–2023 · strength 2.23
  9. Nina G. Steele · 16 shared papers, 2020–2025 · strength 2.07
  10. Zeribe C. Nwosu · 13 shared papers, 2021–2026 · strength 1.83
  11. Anirban Maitra · 4 shared papers, 1 shared grant, 2023–2026 · strength 1.76
  12. Katelyn L. Donahue · 11 shared papers, 2020–2026 · strength 1.65
  13. Yaqing Zhang · 8 shared papers, 2020–2026 · strength 1.58
  14. Samantha B. Kemp · 12 shared papers, 2019–2025 · strength 1.56
  15. Christopher J. Halbrook · 13 shared papers, 2018–2023 · strength 1.51
  16. Padma Kadiyala · 8 shared papers, 2023–2026 · strength 1.47
  17. Emily L. Lasse Opsahl · 5 shared papers, 2025–2026 · strength 1.39
  18. Rosa Elena Menjivar · 9 shared papers, 2021–2026 · strength 1.34
  19. Kyoung Eun Lee · 4 shared papers, 2022–2026 · strength 1.29
  20. Ashley M. Mello · 4 shared papers, 2022–2026 · strength 1.29
  21. Ahmed M. Elhossiny · 6 shared papers, 2024–2026 · strength 1.16
  22. Elana Judith Fertig · 1 shared paper, 1 shared grant, 2026 · strength 1.07
  23. Laura DeLong Wood · 1 shared paper, 1 shared grant, 2026 · strength 1.05
  24. Vaibhav Sahai · 8 shared papers, 2016–2026 · strength 1.05
  25. Li Zhang · 8 shared papers, 2019–2025 · strength 0.91

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.